...

首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >PI3K/AKT/mTOR PATHWAY IS ACTIVATED AFTER IMATINIB SECONDARY RESISTANCE IN GASTROINTESTINAL STROMAL TUMOURS (GISTs)

【24h】

PI3K/AKT/mTOR PATHWAY IS ACTIVATED AFTER IMATINIB SECONDARY RESISTANCE IN GASTROINTESTINAL STROMAL TUMOURS (GISTs)

机译：胃肠道间质瘤（GIST）的Imatinib次生耐药后，PI3K / AKT / mTOR通路得以激活

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Anticancer Research: International Journal of Cancer Research and Treatment》 |2015年第7期|共2页
作者
Li Jian; Dang Yun Z.; Gao Jing; Li Yan Y.; Shen Lin;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. PI3K/AKT/mTOR PATHWAY IS ACTIVATED AFTER IMATINIB SECONDARY RESISTANCE IN GASTROINTESTINAL STROMAL TUMOURS (GISTs) [J] . Li Jian, Dang Yun Z., Gao Jing, Anticancer Research: International Journal of Cancer Research and Treatment . 2015,第7期

机译：胃肠道间质瘤（GIST）的Imatinib次生耐药后，PI3K / AKT / mTOR通路得以激活
2. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. [J] . Haller F, Detken S, Schulten HJ, Annals of surgical oncology . 2007,第2期

机译：关于继发性KIT突变引起的伊马替尼耐药性的胃肠道间质瘤（GIST）新辅助伊马替尼治疗后的手术管理。
3. Surgical Management After Neoadjuvant Imatinib Therapy in Gastrointestinal Stromal Tumours (GISTs) with Respect to Imatinib Resistance Caused by Secondary KIT Mutations [J] . Florian Haller, Sven Detken, Hans-Jürgen Schulten, Annals of Surgical Oncology . 2007,第2期

机译：关于继发性KIT突变引起的伊马替尼耐药的胃肠道间质瘤（GIST）新辅助伊马替尼治疗后的外科治疗
4. Lactoferrin induces the synthesis of vitamin B6 and protects HUVEC functions by activating PDXP and the PI3K/AKT/ERK1/2 pathway [C] . Y.Z.Wang, H.Y.Li, H.G.Yang, The 6th International Symposium on Dairy Cow Nutrition and Milk Quality（第六届“奶牛营养与牛奶质量”国际研讨会）论文集 . -1

机译：乳铁蛋白诱导维生素B6的合成，通过激活PDXP和PI3K / AKT / ERK1 / 2路径来保护HUVEC功能
5. Genetic analysis of the PI3k/AKT/mTOR signaling pathway. [D] . Hutz, Janna Elizabeth. 2010

机译：PI3k / AKT / mTOR信号通路的遗传分析。
6. Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress [O] . Yi Duan, Johannes Haybaeck, Zhihui Yang 2020

机译：胃肠肿瘤中PI3K / AKT / MTOR途径的治疗潜力：理由和进展
7. Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs) [O] . Negri T., Bozzi F., Conca E., 2009

机译：伊马替尼治疗的胃肠道间质瘤（GIST）手术样品中KIT / PDGFRA的致癌和配体依赖性激活

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号